Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.

10/01/2026, 12:30 PM • The Motley Fool

Homozygous Familial Hypercholesterolemia (HoFH) - 7MM Market, Epidemiology, and Forecast - 2036 | RNAi and Targeted Therapies Expand Uptake and Investment Opportunities

The HoFH market is expected to expand through 2036, driven by improved genetic screening, earlier diagnosis, and adoption of targeted lipid-lowering therapies. With approximately 1,840 diagnosed prevalent cases in the 7MM in 2025, the market is shifting toward long-acting, receptor-independent therapies including RNA interference agents and ANGPTL3 inhibitors. Key unmet needs include limited treatment efficacy for patients with minimal LDL receptor function, delayed diagnosis, and high treatment burden.

09/30/2026, 4:59 AM • GlobeNewswire

Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?

Regeneron Pharmaceuticals stock has underperformed this year, down around 1%, but the company demonstrated strong fundamentals in its last earnings report with 17% revenue growth and impressive drug sales. With a modest valuation (19x trailing earnings vs. S&P 500's 23x), a robust pipeline of 50 product candidates, and upcoming Q3 earnings on Oct. 30, analysts suggest the stock could be poised for a rally and represents a solid value buy for long-term investors.

09/28/2026, 1:05 PM • The Motley Fool

Is Regeneron Stock a Bargain Below $800?

Regeneron Pharmaceuticals' stock has declined from over $1,000 to below $800 over the past two years, primarily due to challenges with its Eylea product facing biosimilar competition. However, the company shows strong fundamentals with 17% revenue growth driven by Dupixent, successful mitigation of Eylea losses through its HD formulation, and promising pipeline candidates including the weight-loss drug olatorepatide. The analyst views the stock as attractive at current levels given its long-term growth prospects and shareholder return programs.

09/22/2026, 3:15 PM • The Motley Fool

Co-development Deals in Pharmaceuticals and Biotechnology 2016-2026 | Pharmaceutical Co-Development Deals Reshape R&D Strategies as Companies Share Risk, Costs and Commercial Opportunities

A comprehensive market research report analyzing co-development deals in pharmaceuticals and biotechnology from 2016-2026 has been released. The report covers deal structures, financial terms, the top 25 most active dealmakers, and provides access to actual SEC-filed contract documents. Co-development partnerships are highlighted as a strategic approach for companies to share R&D costs, risks, and commercial opportunities while accelerating product development timelines.

09/22/2026, 10:59 AM • GlobeNewswire

Parexel to Lead Sessions at DPHARM 2026 on AI, Talent and the Future of Clinical Operations

Parexel announced it will lead three expert panel sessions at DPHARM 2026 in Boston on enterprise AI adoption, workforce readiness, and patient-centric drug development. The company showcased its proprietary ParexelAI suite, which has delivered significant efficiency gains including 50% reduction in site selection timelines, 30% reduction in clinical study report preparation time, and 60% reduction in safety literature screening. CEO Peyton Howell and other executives will moderate discussions with leaders from major pharmaceutical companies including AbbVie, AstraZeneca, Boehringer Ingelheim, Regeneron, and Merck.

09/14/2026, 9:00 AM • GlobeNewswire

REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit

A securities class action lawsuit has been filed against Regeneron Pharmaceuticals over allegations that the company made false and misleading statements regarding a Phase 3 clinical trial of Fianlimab for melanoma treatment. The trial failed to reach statistical significance on its primary endpoint, causing an $11 billion market cap loss. Investors claim Regeneron concealed flawed statistical assumptions and slow event rates while expressing confidence in the trial's success. The lead plaintiff deadline is September 14, 2026.

09/12/2026, 2:47 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Pomerantz LLP is investigating potential securities fraud claims against EyePoint, Inc. following the company's announcement on August 17, 2026, that its DURAVYU drug failed to meet primary endpoints in the LUGANO Phase 3 clinical trial for wet AMD treatment. The failure to demonstrate superiority over Regeneron's Eylea resulted in a 66.98% stock price decline, falling from approximately $14.75 to $4.87 per share.

09/08/2026, 5:52 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN

Pomerantz Law Firm has filed class action lawsuits against Regeneron Pharmaceuticals, Capricor Therapeutics, and GPGI, Inc. for alleged securities fraud. The primary focus is on Regeneron, where a Phase III clinical trial for Fianlimab-Libtayo failed to meet its primary endpoint, causing the stock to decline significantly on two separate occasions in April and May 2026. Investors with losses are urged to contact the firm by September 14, 2026, to potentially become lead plaintiffs.

09/08/2026, 4:58 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Bloom Energy Corporation of Class Action Lawsuit and Upcoming Deadlines – BE

Pomerantz Law Firm has filed class action lawsuits against Bloom Energy Corporation, Primoris Services Corporation, and Regeneron Pharmaceuticals, Inc., alleging securities fraud and unlawful business practices. The Bloom Energy lawsuit was triggered by a Hunterbrook Media report alleging the company relies on Chinese scandium in its supply chain, causing the stock to fall 5.67% on July 8, 2026. Investors have until September 28, 2026, to request Lead Plaintiff status.

09/08/2026, 4:51 PM • GlobeNewswire

Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - SNS Insider

The global atopic dermatitis drugs market is projected to grow from USD 15.92 billion in 2025 to USD 33.42 billion by 2035, driven by increased adoption of biologic therapies, JAK inhibitors, and novel treatments. North America leads with 36% market share, while Asia-Pacific shows the fastest growth. Biologics dominate with 42% market share, though high costs and JAK inhibitor safety warnings present challenges.

09/04/2026, 8:30 PM • GlobeNewswire

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

The biotech industry is experiencing a strong rebound in 2026. While both Vertex Pharmaceuticals and Regeneron are attractive options, Vertex emerges as the better buy due to its stronger competitive advantage in cystic fibrosis drugs with patent protection until the late 2030s, diversified pipeline targeting high-need areas with less competition, and lower execution risk compared to Regeneron's dependence on weight-loss candidates and defending its Dupixent franchise against increasing competition.

09/04/2026, 2:30 PM • The Motley Fool

REGN 12-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit

A securities class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly making false and misleading statements about its Phase 3 clinical trial of Fianlimab for melanoma treatment. The company reportedly failed to disclose that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. After initially expressing confidence in the trial, Regeneron altered the trial protocol in November 2025 without timely disclosure and ultimately announced on May 15, 2026 that the trial failed to reach statistical significance, resulting in an $11 billion market cap loss.

09/02/2026, 6:36 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging that the company made materially false and misleading statements regarding its Phase III Fianlimab-Libtayo study. The complaint claims the study's preliminary statistical assumptions were flawed, the treatment arm showed no meaningful clinical differentiation from standard therapies, and the study was unlikely to achieve statistical significance on its primary endpoint. The class period covers purchases between August 1, 2025 and May 15, 2026.

09/02/2026, 12:00 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging that the company made materially false and misleading statements regarding its Phase III Fianlimab-Libtayo study. The complaint claims the study's preliminary statistical assumptions were flawed, the treatment arm showed no meaningful clinical differentiation from standard therapies, and the study was unlikely to achieve statistical significance on its primary endpoint. Investors who purchased Regeneron securities between August 1, 2025 and May 15, 2026 are encouraged to join the case.

08/30/2026, 12:00 PM • GlobeNewswire